A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy

Condition:   Carcinoma, Non-small Cell Lung Interventions:   Biological: nivolumab;   Biological: ipilimumab;   Drug: cabozantinib;   Drug: docetaxel;   Biological: ramucirumab;   Drug: lucitanib Sponsor:   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Conclusions: Sebaceous carcinoma currently has few effective adjuvant treatment options. The expression of PD-1, PD-L1, and PD-L2 on infiltrating immune cells and PD-L2 on tumor cells restrains T-cells from full activation and proliferation, therefore limiting the antitumor effect of T-cells, tipping the balance toward unopposed tumor progression. Consequently, PD-1 or PD-L1 inhibitors may have a role in sebaceous carcinoma treatment. Given the prevalence of PD-L2 expression in sebaceous carcinoma and the lack of PD-L2 blockade therapy available, PD-1 blockade may provide benefit over PD-L1 inhibitors. PD-1 blockade in c...
Source: Ophthalmic Plastic and Reconstructive Surgery - Category: Opthalmology Tags: Original Investigations Source Type: research
Conclusion: Bronchoscopic re-biopsy for progressive lung cancer is feasible and safe. Histological change can be detected in a considerable number of patients, which is potentially valuable information for guidance of subsequent treatment.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Yicheng Ni Cancer remains a major cause of death globally. Given its relapsing and fatal features, curing cancer seems to be something hardly possible for the majority of patients. In view of the development in cancer therapies, this article summarizes currently available cancer therapeutics and cure potential by cancer type and stage at diagnosis, based on literature and database reviews. Currently common cancer therapeutics include surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. However, treatment with curative intent by these methods are mainly eligible for patients with localized diseas...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Conditions:   Metastatic Lung Non-Small Cell Carcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8 Interventions:   Procedure: Positron Emission Tomography;   Procedure: Computed Tomography;   Drug: Chemotherapy;   Biological: Immunotherapy;   Radiation: Radiation Therapy Sponsors:   University of Washingto...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Carcinoma, Non-small Cell Lung Interventions:   Biological: nivolumab;   Biological: ipilimumab;   Drug: cabozantinib;   Drug: docetaxel;   Biological: ramucirumab;   Drug: lucitanib Sponsor:   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Metastatic Lung Non-Small Cell Carcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8 Interventions:   Procedure: Positron Emission Tomography;   Procedure: Computed Tomography;   Drug: Chemotherapy;   Biological: Immunotherapy;   Radiation: Radiation Therapy Sponsors:   University of Washingto...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Metastatic Lung Non-Small Cell Carcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8 Interventions:   Procedure: Positron Emission Tomography;   Procedure: Computed Tomography;   Drug: Chemotherapy;   Biological: Immunotherapy;   Radiation: Radiation Therapy Sponsors:   University of Washingto...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Carcinoma, Non-small Cell Lung Interventions:   Biological: nivolumab;   Biological: ipilimumab;   Drug: cabozantinib;   Drug: docetaxel;   Biological: ramucirumab;   Drug: lucitanib Sponsor:   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Metastatic Lung Non-Small Cell Carcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8 Interventions:   Procedure: Positron Emission Tomography;   Procedure: Computed Tomography;   Drug: Chemotherapy;   Biological: Immunotherapy;   Radiation: Radiation Therapy Sponsors:   University of Washingto...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Carcinoma, Non-small Cell Lung Interventions:   Biological: nivolumab;   Biological: ipilimumab;   Drug: cabozantinib;   Drug: docetaxel;   Biological: ramucirumab;   Drug: lucitanib Sponsor:   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Docetaxel | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study | Taxotere | Yervoy